DAB389interleukin-6Alternative Names: DAB389IL-6; interleukin-6 diphtheria toxin chimeric protein
Latest Information Update: 14 Feb 2001
At a glance
- Originator Seragen
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Feb 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 23 Nov 1998 New profile
- 23 Nov 1998 Preclinical development for Cancer in USA (Unknown route)